Cargando…
Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor” [Volume 14, Issue 9, September 2021, 101152]
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Neoplasia Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777136/ https://www.ncbi.nlm.nih.gov/pubmed/35042060 http://dx.doi.org/10.1016/j.tranon.2022.101344 |
| _version_ | 1784636997983272960 |
|---|---|
| author | Koga, Satoko Onishi, Hideya Masuda, Shogo Fujimura, Akiko Ichimiya, Shu Nakayama, Kazunori Imaizumi, Akira Nishiyama, Kenichi Kojima, Masayuki Miyoshi, Kei Nakamura, Katsuya Umebayashi, Masayo Morisaki, Takashi Nakamurab, Masafumi |
| author_facet | Koga, Satoko Onishi, Hideya Masuda, Shogo Fujimura, Akiko Ichimiya, Shu Nakayama, Kazunori Imaizumi, Akira Nishiyama, Kenichi Kojima, Masayuki Miyoshi, Kei Nakamura, Katsuya Umebayashi, Masayo Morisaki, Takashi Nakamurab, Masafumi |
| author_sort | Koga, Satoko |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8777136 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Neoplasia Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87771362022-01-26 Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor” [Volume 14, Issue 9, September 2021, 101152] Koga, Satoko Onishi, Hideya Masuda, Shogo Fujimura, Akiko Ichimiya, Shu Nakayama, Kazunori Imaizumi, Akira Nishiyama, Kenichi Kojima, Masayuki Miyoshi, Kei Nakamura, Katsuya Umebayashi, Masayo Morisaki, Takashi Nakamurab, Masafumi Transl Oncol Corrigendum Neoplasia Press 2022-01-15 /pmc/articles/PMC8777136/ /pubmed/35042060 http://dx.doi.org/10.1016/j.tranon.2022.101344 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Corrigendum Koga, Satoko Onishi, Hideya Masuda, Shogo Fujimura, Akiko Ichimiya, Shu Nakayama, Kazunori Imaizumi, Akira Nishiyama, Kenichi Kojima, Masayuki Miyoshi, Kei Nakamura, Katsuya Umebayashi, Masayo Morisaki, Takashi Nakamurab, Masafumi Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor” [Volume 14, Issue 9, September 2021, 101152] |
| title | Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor” [Volume 14, Issue 9, September 2021, 101152] |
| title_full | Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor” [Volume 14, Issue 9, September 2021, 101152] |
| title_fullStr | Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor” [Volume 14, Issue 9, September 2021, 101152] |
| title_full_unstemmed | Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor” [Volume 14, Issue 9, September 2021, 101152] |
| title_short | Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor” [Volume 14, Issue 9, September 2021, 101152] |
| title_sort | corrigendum to “ptpn3 is a potential target for a new cancer immunotherapy that has a dual effect of t cell activation and direct cancer inhibition in lung neuroendocrine tumor” [volume 14, issue 9, september 2021, 101152] |
| topic | Corrigendum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777136/ https://www.ncbi.nlm.nih.gov/pubmed/35042060 http://dx.doi.org/10.1016/j.tranon.2022.101344 |
| work_keys_str_mv | AT kogasatoko corrigendumtoptpn3isapotentialtargetforanewcancerimmunotherapythathasadualeffectoftcellactivationanddirectcancerinhibitioninlungneuroendocrinetumorvolume14issue9september2021101152 AT onishihideya corrigendumtoptpn3isapotentialtargetforanewcancerimmunotherapythathasadualeffectoftcellactivationanddirectcancerinhibitioninlungneuroendocrinetumorvolume14issue9september2021101152 AT masudashogo corrigendumtoptpn3isapotentialtargetforanewcancerimmunotherapythathasadualeffectoftcellactivationanddirectcancerinhibitioninlungneuroendocrinetumorvolume14issue9september2021101152 AT fujimuraakiko corrigendumtoptpn3isapotentialtargetforanewcancerimmunotherapythathasadualeffectoftcellactivationanddirectcancerinhibitioninlungneuroendocrinetumorvolume14issue9september2021101152 AT ichimiyashu corrigendumtoptpn3isapotentialtargetforanewcancerimmunotherapythathasadualeffectoftcellactivationanddirectcancerinhibitioninlungneuroendocrinetumorvolume14issue9september2021101152 AT nakayamakazunori corrigendumtoptpn3isapotentialtargetforanewcancerimmunotherapythathasadualeffectoftcellactivationanddirectcancerinhibitioninlungneuroendocrinetumorvolume14issue9september2021101152 AT imaizumiakira corrigendumtoptpn3isapotentialtargetforanewcancerimmunotherapythathasadualeffectoftcellactivationanddirectcancerinhibitioninlungneuroendocrinetumorvolume14issue9september2021101152 AT nishiyamakenichi corrigendumtoptpn3isapotentialtargetforanewcancerimmunotherapythathasadualeffectoftcellactivationanddirectcancerinhibitioninlungneuroendocrinetumorvolume14issue9september2021101152 AT kojimamasayuki corrigendumtoptpn3isapotentialtargetforanewcancerimmunotherapythathasadualeffectoftcellactivationanddirectcancerinhibitioninlungneuroendocrinetumorvolume14issue9september2021101152 AT miyoshikei corrigendumtoptpn3isapotentialtargetforanewcancerimmunotherapythathasadualeffectoftcellactivationanddirectcancerinhibitioninlungneuroendocrinetumorvolume14issue9september2021101152 AT nakamurakatsuya corrigendumtoptpn3isapotentialtargetforanewcancerimmunotherapythathasadualeffectoftcellactivationanddirectcancerinhibitioninlungneuroendocrinetumorvolume14issue9september2021101152 AT umebayashimasayo corrigendumtoptpn3isapotentialtargetforanewcancerimmunotherapythathasadualeffectoftcellactivationanddirectcancerinhibitioninlungneuroendocrinetumorvolume14issue9september2021101152 AT morisakitakashi corrigendumtoptpn3isapotentialtargetforanewcancerimmunotherapythathasadualeffectoftcellactivationanddirectcancerinhibitioninlungneuroendocrinetumorvolume14issue9september2021101152 AT nakamurabmasafumi corrigendumtoptpn3isapotentialtargetforanewcancerimmunotherapythathasadualeffectoftcellactivationanddirectcancerinhibitioninlungneuroendocrinetumorvolume14issue9september2021101152 |